Perspective Therapeutics Equity 2024

Perspective Therapeutics Aktienanalyse

What does Perspective Therapeutics do?

The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. Perspective Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Perspective Therapeutics's Equity

Perspective Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Perspective Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Perspective Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Perspective Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Perspective Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Perspective Therapeutics Stock

What is the equity of Perspective Therapeutics this year?

Perspective Therapeutics has equity of 75.18 M USD this year.

What was the equity of Perspective Therapeutics compared to the previous year?

The equity of Perspective Therapeutics has increased/decreased by 37.59% increased compared to the previous year.

What impact does a high equity have on investors of Perspective Therapeutics?

A high equity is advantageous for investors of Perspective Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Perspective Therapeutics?

A low equity can be a risk for investors of Perspective Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Perspective Therapeutics affect the company?

An increase in equity of Perspective Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Perspective Therapeutics affect the company?

A reduction in equity of Perspective Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Perspective Therapeutics?

Some factors that can affect the equity of Perspective Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Perspective Therapeutics so important for investors?

The equity of Perspective Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Perspective Therapeutics take to change the equity?

To change equity, Perspective Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Perspective Therapeutics pay?

Over the past 12 months, Perspective Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Perspective Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Perspective Therapeutics?

The current dividend yield of Perspective Therapeutics is .

When does Perspective Therapeutics pay dividends?

Perspective Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Perspective Therapeutics?

Perspective Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Perspective Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Perspective Therapeutics located?

Perspective Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Perspective Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Perspective Therapeutics from 6/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Perspective Therapeutics pay the last dividend?

The last dividend was paid out on 6/17/2024.

What was the dividend of Perspective Therapeutics in the year 2023?

In the year 2023, Perspective Therapeutics distributed 0 USD as dividends.

In which currency does Perspective Therapeutics pay out the dividend?

The dividends of Perspective Therapeutics are distributed in USD.